Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Has there been any update of how well the company did in 2023 and what the outlook is for 2024 as well any update on new product development etc.
The last real RNS with that type of info was on "27 Sep 2023 - Half-year Report" which covered to 30 June 2023. I'd have thought the full year report would have been released by now.
The RNS is very good news and I expect to see regular news flow this year. It's good to see they are continuing to sell Slimbiome to more markets and partners. Even if they got half the forecast for YR 1 in revenue, so £600k, that would mean they should easily reach record revenue for the year ahead for slimbiome and easily be profitable.
I do believe the SP would be higher, but might stay in this range as "Finance Yorkshire Seedcorn Fund (FYSCF)" seems to be selling slowly into the market, so that kind of is keeping the share price bogged down.
@AustinTexas, I had a quick look at some sugar suppliers, you may have heard of Kent Foods, they had this on their website:
"Kent Foods is Europe’s largest independent supplier of sugars, selling 350,000 tonnes of sugar every year. Here at Kent Foods, we are completely independent. This means that we can advise you on the best wholesale sugar for your requirements from our own Sucranna Sugar range to the ranges of the World's major refiners."
As this is just 1 independent supplier, and there are many others, I think 100K per annum for us is very good for a starter and as Sweetbiotix get's more established, I can see that increasing rapidly in a 2-3 years times. We also have the supplier across the pond also, and if they were to do a similar preliminary forecast of 100k tonne per annum as well, that'll be 200k tonne.
I think it's a very good update. It would have been nice to know if they had hit profitability in all the divisions as was the aim on a month-by-month basis by Dec 23. Good to see us concentrating on the bigger markets now.
As regards to Sweetbiotix, that was one of the main things that attracted me to Optibiotix many years ago (too bad I got in when share price was a lot higher compared to now), it definitely has been slow going, but 2024 is the year for us. I think someone was trying to compare the 100K tonne to what Stevia produce, but I don't think we can make a comparison to that as ours is a bulk sugar replacement (so if product has 100g of sugar, I assume they would use roughly around 100g of sweetbiotix, we need a lot more info around this though ), whereas Stevia is just a sweetener so only need a tiny bit to sweeten stuff.
Awesome to hear it's already been added to a finished product already and that we should expect to see many more throughout 2024. I'm finally really excited for this year after waiting patiently for several years.
Not to forget we still have "MicroBiome Modulators" in the pipeline, which could be massive. Does anyone know if any timelines have been mentioned around that?
What happens if Probiotix did move to AIM. Would our shares automatically get moved over to AIM?
I currently have mine in a iWeb account, but as they don't offer Aquiss exchange, I would have to move them to a provider who does. I was hoping Probiotix would move to AIM.
Excellent update. Everything seems to being going to schedule as per last update.
"Manufacturing scale up with Firmenich slowed during and after their merger with DSM, as anticipated, but resumed in late autumn 2023 as Firmenich moved manufacturing scale up from its contract manufacturer to DSM's in-house manufacturing facilities. Ongoing discussions indicate strong partner support on increasing the anticipated scale of production and supply given the enlarged group, DSM-Firmenich, now have access to global manufacturing and distribution capability. "
Seems there's a lot of increased partner interest so they are increasing manufacturing scale further and as it's in-house now for DSM, should be quicker.
We should see now Opti concentrating of selling it this year, hopefully we see plenty of deals being signed throughout the year. I think summer especially will be when we get some decent deals done.
The RNS mentioned "We anticipate most results should be returned over the summer when we can start partner application development and launch plans." regarding " Liquid and freeze-dried products ".
So I'm hoping we'll hear some good news on how this has gone maybe late September time. Thereafter I hope we'll be kept up to date getting Sweetbiotix in actual products and possible launch plans by different companies.
If the liquid and freeze-dried process goes well which is the last major step, I think the 4th Quarter of 2023 and first half of 2024 we'll start getting regular updates on possible product development/launch plans about our partners that plan to make use of SweetBiotix. I can see the bigger partner's might not allow news to get out until they are close to launching, so we'll require patience.
For me, I think 2024 is going to be a fantastic year for us. And that's not even mentioning the "Microbiome Modulators" which SOH said is only a little behind sweetbiotix, and believes that can be as big as what Sweetbiotix could be.
For us LTH, I think most of us expected to be at this stage about 2-3 years ago, but it's good to see us reaching there finally.
I've also got the ones we got because of the OPTI stock divi. I would have definitely bought more shares at these prices if it had been on AIM. Unfortunately all my shares are held with stockbrokers that don't deal with Aquiss, so if I wanted to buy or sell, I would need to transfer the PBX shares to a stockbroker that does deal with Aquiss, I decided to wait and hope PBX get's moved to the AIM exchange.
I think being able to name the companies involved in this RNS, is that it may start attracting attention from other medium/big names to look into sweetbiotix to see what their competitors are doing, and hence may increase number of possible clients faster.
I think the RNS was a really good idea. Though the news in it isn't new, for a new investor (or even existing investors) it has all the information around Sweetbiotix in one place which otherwise would be harder to dig out. It also just highlights the potential of Sweetbiotix were just 1 of the big players to use it commercially. For anyone new, it'll be worth taking a punt on it by buying a small amount.
The reason there's been a big change in share price is, it doesn't take too much interest in the share for the price to move as it's been depressed for quite a while now.
I never understood the need to seperate Probiotix. If the company was making decent profit but the share price wasn't reflecting that then I could understand. It was very premature to do that IMO and especially on Aquiss.
Does anyone know if PBX were to be moved to AIM, would existing shares all transfer over. I have the shares in iWeb, but as they don't have Aquiss exchange, I can't do anything with them, I would have to open an account elsewhere and transfer them somehow.
Optbiotix RNS, nothing new there that we didn't know from previous RNS'. The only thing that's gonna help the share price is once we have confirmed sales of sweetbiotix and revenue from that, which is taking much longer than I ever anticipated.
ProBiotix Health Plc have also released an RNS covering 3 months from 31 March to 30 June. It's very interesting and the figure for end of Aug is £1.12m which is already more than whole figure of 2021. Good to see they have launched in a few more territories Inc China. I'm glad they've given more info around the likely launch in Brazil and Malaysia. I'm quite happy with the direction ProBiotix Health Plc are going and really looking forward to new CEO starting.
The current PBX share price is between 21-22p - https://www.lse.co.uk/SharePrice.asp?shareprice=PBX.PL&share=Probiotix-Health-Plc
I've used 21p in my current calculations.
If you want to know what value the OPTI share price is (and taking PBX share into consideration) a rough estimate would be Current OPTI share price 30p + 11p PBX, so equivalent to 41p overall.
Theanalyzer - Yes, I've calculated how many PBX shares I'll likely get (No. Opti shares x 0.554673) and taken that into consideration when working out what my break-even would be.
I bought all my shares back in 2017/2018 when it was in the 60-80p range, hence why the current price is still a way off yet.
The biggest disappointment has been that we are definitely at least 2.5 years behind where I expected us to be Revenue wise at this point, but still believe we will be very profitable (a lot of this rides on Sweetbiotix being a big success and LP-LDL being more widely available in Yogurts as that's the preferred way a lot of people consume good bacteria) and this will provide me a good dividend in future years.
On a positive note, Slimbiome is doing much better than I expected.
Excellent news. As it's "one of the world's largest Stevia suppliers" it should open doors to lots of businesses.
Finally good to see the SP going in right direction. It's still a lot lower than my average, but I'm hopefully we start seeing solid financially impacting RNS over next few months.
I think there's a very good chance of Revenue being £4m or possibly more.
I'm a little disappointed there's not much of an update regarding Sweetbiotix, I was hoping they would have progressed that a lot more. Sweetbiotix is what I see really giving this share a boost, but until then I don't think there will be much movement on share price.
Degiro replied to my enquiry regarding the PBX in-specie.
"We are awaiting the shares (formal status: pending payment). The minimum holding period with the nominee is 9 months, so this will be after January 23."
So I expect we all will hear from our Brokers once 9 Months have elapsed.
With Opti we currently have Slimbiome, Wellbiome, Leanbiome as well as the Modulator technology etc. But the golden goose is definitely Sweetbiotix, if in the next few months they are able to announce a big deal with a major player, then I do see the share price will definitely shoot up considerably. As we know, things have taken a lot longer than most of us assumed, so it's just a waiting game.